Loading...
XSHG
603387
Market cap607mUSD
Jul 10, Last price  
8.28CNY
1D
1.97%
1Q
-18.74%
IPO
-9.71%
Name

Getein Biotech Inc

Chart & Performance

D1W1MN
XSHG:603387 chart
P/E
19.03
P/S
4.03
EPS
0.44
Div Yield, %
2.22%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
-1.48%
Revenues
1.04b
-10.51%
73,640,347154,195,412210,293,366276,420,264369,090,356488,582,765686,238,288968,204,2841,123,335,6171,401,701,3851,821,860,7021,369,162,2551,164,798,9361,042,425,297
Net income
221m
-1.33%
21,960,30965,627,76475,135,879105,066,842138,356,908193,988,373249,612,051339,672,024304,733,140398,990,050498,909,982279,771,916223,636,491220,661,381
CFO
414m
-2.16%
23,799,01359,715,98498,534,931121,729,000155,914,635191,912,890187,097,698225,732,761185,468,524432,364,576482,957,526333,220,661422,998,055413,855,770
Dividend
Sep 15, 20250.09 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Getein Biotech, Inc. is an enterprise primarily focused on the research, development, manufacturing, and global distribution of in vitro diagnostic (IVD) solutions. Founded in 2002 and based in Nanjing, China, the company offers a comprehensive array of diagnostic products. This includes a variety of diagnostic reagents, advanced analytical instruments, and crucial calibrators. Getein also supplies foundational raw materials for reagents, such as monoclonal and polyclonal antibodies, antigens, antiserum, and microspheres. Its extensive product line caters to diverse medical fields, encompassing diagnostics for cardiac markers, inflammatory conditions, renal function, blood coagulation, thyroid disorders, fertility assessments, diabetes care, and thrombus detection. These offerings broadly serve applications in cardiovascular, inflammatory, diabetes, reproductive, renal, hepatic, and other key health areas.
IPO date
Jul 17, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT